TP53 缺失通过上调 NF-κB-IFN-β-MHC-Ia 信号促进骨肉瘤对 NK 细胞的抵抗
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
COVID-19 患者接受间充质干细胞治疗后的血液学参数评估
英文原题：Evaluation of Hematologic Parameters in Patients with COVID-19 Following Mesenchymal Stem Cell Therapy.
查看英文原题
Evaluation of Hematologic Parameters in Patients with COVID-19 Following Mesenchymal Stem Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前，严重急性呼吸综合征冠状病毒2正在传播，已导致超过188百万确诊病例和超过4,059,101例死亡。当前，已有几项临床试验在2019冠状病毒病（COVID-19）患者中使用间充质干细胞（MSC）疗法。这些细胞已显示出安全性和有效性，暗示其在COVID-19患者中具有有前景的临床应用。研究表明，血液学指标的异常，如白细胞计数、中性粒细胞增多、中性粒细胞与淋巴细胞比值升高、炎症标志物和乳酸脱氢酶，可用于评估COVID-19疾病的严重程度以及MSC治疗后的治疗反应。我们的研究旨在综述血液学因素在确定COVID-19患者对MSC治疗的反应性和疾病严重程度中的作用。
展开英文摘要原文
At present, severe acute respiratory syndrome coronavirus 2 is spreading and has caused over 188 million confirmed patients and more than 4,059,101 deaths. Currently, several clinical trials are done using mesenchymal stem cell (MSC) therapy in patients with coronavirus disease 2019 (COVID-19). These cells have shown safety and effectiveness, implying a promising clinical application in patients with COVID-19.
Studies have shown that abnormalities in hematological measures such as white blood cells count, neutrophilia, elevated neutrophil to lymphocyte ratio, inflammatory markers, and lactate dehydrogenase can be used to assess the severity of COVID-19 disease and the response to therapy following MSC treatment.
Our study has aimed to review the role of hematological factors in determination of responsiveness to MSC therapy and disease severity in COVID-19 patients.
论文信息
- 作者
- Bakhshi H、Soleimani M、Soufizomorrod M、Kooshkaki O
- 第一作者单位
- Department of Hematology and Cell Therapy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.Iran
- 通讯作者单位
- Department of Immunology, Birjand University of Medical Sciences, Birjand, Iran.Iran
- 期刊
- DNA and cell biology2022 Aug
- 原文标识
- PubMed 35914059 · DOI 10.1089/dna.2021.1198